Skip to content

Investor Relations

Page Path 'Breadcrumb':

Investor Relations

Corporate Profile

Ardea Biosciences, Inc. (NASDAQ: RDEA), headquartered in San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases.

Stock Quote
RDEA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$31.73
Change (%) Stock is Up 0.04 (0.13%)
Volume346,743
Data as of 05/18/12 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Presentations
Ardea Company Update, March 9, 2012

Recent NewsMore News >>
DateTitle 
05/07/12Ardea Biosciences Announces First Quarter 2012 Financial Results
SAN DIEGO, CA, May 07, 2012 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today announced first quarter 2012 financial results. On April 22, 2012, AstraZeneca and Ardea Biosciences announced that they had entered into a definitive merger agreement pursuant to which AstraZeneca will acquire Ardea for $32 per share in cash for a total transaction value of ... 
Printer Friendly Version
04/23/12AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout
SAN DIEGO,CA, Apr 23, 2012 (MARKETWIRE via COMTEX) -- AstraZeneca and Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics. Ardea's clinically most advanced product candidate, lesinurad (formerly known as RDEA594), is currently in Phase III development as a potential treatment f... 
Printer Friendly Version
03/09/12Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2011 Financial Results
SAN DIEGO, CA, Mar 09, 2012 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and announced fourth quarter and full-year 2011 financial results. "The proceeds of $157.6 million from our recent financing, added to our existing cash balance, put us in an excellent financial position," commented Barry D. Quart, PharmD, Arde... 
Printer Friendly Version
02/29/12Ardea Biosciences to Present at Upcoming Investor Conferences
SAN DIEGO, CA, Feb 29, 2012 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the following upcoming investor conferences in March 2012: -- Cowen and Company 32nd Annual Health Care Conference in Boston, MA. Presentation: 2:10 p.m. EST on Monday, March 5, 2012. -- ROTH 24th Annual OC Growth Stock Conference in Laguna Niguel, CA. Presentation: 8:30 a.m. PDT on Tuesd... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/31/12
2:00 p.m. PT
Ardea Biosciences, Inc. Annual Shareholder Meeting
Location4939 Directors Place
San Diego, CA 92121

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.